×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

cll

Nitin Jain, M.D.
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.
Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.
 
Heather Millar
Researchers are identifying targets to treat chronic lymphocytic leukemia.
Gina Columbus
Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).
 
Edward McClain
As Ed completes his final chemo cycle, he loses a friend.
Laura Panjwani
Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.
Gina Columbus
The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.
Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.
Jason M. Broderick
There are now more personalized treatment options for patients with CLL. 
Silas Inman
Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL. 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable